Results 131 to 140 of about 579,008 (311)

The sodium-dependent D-glucose transport protein of Helicobacter pylori

, 2008
Helicobacter pylori is a gram-negative pathogenic microaerophile with a particular tropism for the mucosal surface of the gastric epithelium. Despite its obligatory microaerophilic character, it can metabolize D-glucose and/or D-galactose in both ...
Kim E. Bettaney, Polaczek, Julia, Lars‐Oliver Essen, Massoud Saidijam, Hope, Ryan, Shibayama, Keigo, Henderson, Peter J.F., Saidijam, Massoud, Jocelyn M. Baldwin, Stephen A. Baldwin, Essen, Lars-Oliver, Psakis, Georgios, Baldwin, Jocelyn M., Bettaney, Kim E., Peter J. F. Henderson, Baldwin, Stephen A., Ryan Hope, Julia Polaczek, Richard C. Essenberg, Georgios Psakis, Keigo Shibayama, Essenberg, Richard C.   +21 more
core   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Influence of probiotics and deoxycholate on azathioprine transport in the PAMPA model: insights into pharmacomicrobiomics and interindividual variability in drug response

Frontiers in Pharmacology
IntroductionInterindividual variability in drug response presents a major clinical challenge, necessitating a deeper understanding of contributing factors.
Maja Đanić, Nebojša Pavlović, Natalija Dedić, Dragana Zaklan, Slavica Lazarević, Bojan Stanimirov, Momir Mikov   +6 more
doaj   +1 more source

Food Additives Inhibit Intestinal Drug Transporters but Have Limited Effect on In Vitro Drug Permeability

Food additives are chemical substances that are added to processed food to improve its flavor, texture, or appearance. Food additives can inhibit intestinal transporters, such as breast cancer resistance protein (BCRP), multidrug resistance associated ...
Stenberg, Emilia, Sjöstedt, Noora Karoliina, Kidron, Heidi Tuulia, Suominen, Laura Maria Vilhelmiina   +3 more
core   +1 more source

Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model

, 2012
Background: The blood-brain barrier (BBB) represents an insurmountable obstacle for most drugs thus obstructing an effective treatment of many brain diseases.
Tikva Vogel, Zensi, Anja, von Briesen Hagen, Kreuter Jörg, Worek Franz, Tschickardt, Sabrina E., Sascha L Wien, Jörg Kreuter, Wien Sascha L., Vogel Tikva, Sabrina E Tschickardt, Wladislaw Maier, Vogel, Tikva, Sylvia Wagner, Claus U Pietrzik, Maier Wladislaw, Zensi Anja, Wien, Sascha L., Maier, Wladislaw, Tschickardt Sabrina E., Wagner, Sylvia, Pietrzik Claus U., Anja Zensi, Kreuter, Jörg, Worek, Franz, Hagen von Briesen, Pietrzik, Claus Ulrich, Briesen, Hagen von, Wagner Sylvia, Franz Worek   +29 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC.

, 2006
The aim of this study is to develop a once-daily sustained release matrix tablet of ibuprofen using hydroxypropyl methylcellulose (HPMC) as release controlling factor and to evaluate drug release parameters as per various release kinetic models. In order
Tazeen, Jaweria, Merchant, Hamid A., Shoaib, M Harris, Yousuf, Rabia Ismail   +3 more
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source